Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01464671 · ClinicalTrials.gov registry record · Phase 4

Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention

A Phase 4 study, sponsored by Stony Brook University.

Terminated
Registry status
Phase 4
Development phase
260
Enrollment target

NCT01464671: Clinical Trial Phase 4 study, sponsored by Stony Brook University.

NCT01464671 is a Phase 4 study that was terminated before completion, run by Stony Brook University. The registered enrollment target is 260 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01464671, a Phase 4 study, was terminated before completion, sponsored by Stony Brook University.

TERMINATED
Registry status
Phase 4
Development phase
260 participants
Enrollment target

Study Summary

The objective of the study is to assess the safety and efficacy of Angiomax® (bivalirudin) versus unfractionated heparin (UFH) in patients presenting with stable angina or silent ischemia (positive stress test without chest pain) that undergo percutaneous coronary intervention (PCI). The primary endpoint of the study will be major and minor bleeding events, defined by the REPLACE-2 trial definition, during the index hospitalization and up to 30 days post discharge.

Primary Outcome

The primary endpoint of the study will be major and minor bleeding events, defined by the REPLACE-2 trial definition during the index hospitalization and up to 30 days post discharge.

Interventions

  • DRUG Heparin
  • DRUG Bivalirudin

Trial Details

FieldValue
Enrollment Target 260 participants
Start Date 2009-07
Est. Completion 2014-09
Phase Phase 4
Stony Brook University

127 total trials

Why NCT01464671 stopped before completion

NCT01464671 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 2 interventions - of which Heparin is the first listed.

NCT01464671 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01464671 about?

NCT01464671 is a clinical study titled "Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention". The objective of the study is to assess the safety and efficacy of Angiomax® (bivalirudin) versus unfractionated heparin (UFH) in patients presenting with stable angina or silent ischemia (positive stress test without chest pain) that undergo percutaneous coronary intervention (PCI). The primary en...

What is the current status of trial NCT01464671?

This trial is currently terminated. It is a Phase 4 study. The enrollment target is 260 participants. The study started on 2009-07. Estimated completion is 2014-09.

What interventions are being tested in trial NCT01464671?

The interventions under investigation include: Heparin (DRUG), Bivalirudin (DRUG).

Who is sponsoring clinical trial NCT01464671?

This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01464671's enrollment target sits among peer trials

260 326th of 2000 higher than 1,670 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02283996 · 260 participants · Phase 4

    Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment

  • NCT03276793 · 260 participants · NA

    Brain Connectivity in Depression

  • NCT03407469 · 260 participants

    Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization

  • NCT03713125 · 260 participants · NA

    Executive Function in Early Childhood

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01464671, the US trial registry maintained by the National Library of Medicine. NCT01464671 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.